This statistic displays the research and development phase III cost of the top 10 drugs based on net present value, as of 2015. Actelion's Uptravi had a total R&D phase III cost of 185 million U.S. dollars. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
Phase III R&D costs of projected top orphan drugs as of 2015 (in million U.S. dollars)*
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Evaluate. (October 30, 2015). Phase III R&D costs of projected top orphan drugs as of 2015 (in million U.S. dollars)* [Graph]. In Statista. Retrieved November 23, 2024, from https://www.statista.com/statistics/373408/orphan-drugs-by-phase-iii-development-cost/
Evaluate. "Phase III R&D costs of projected top orphan drugs as of 2015 (in million U.S. dollars)*." Chart. October 30, 2015. Statista. Accessed November 23, 2024. https://www.statista.com/statistics/373408/orphan-drugs-by-phase-iii-development-cost/
Evaluate. (2015). Phase III R&D costs of projected top orphan drugs as of 2015 (in million U.S. dollars)*. Statista. Statista Inc.. Accessed: November 23, 2024. https://www.statista.com/statistics/373408/orphan-drugs-by-phase-iii-development-cost/
Evaluate. "Phase Iii R&d Costs of Projected Top Orphan Drugs as of 2015 (in Million U.S. Dollars)*." Statista, Statista Inc., 30 Oct 2015, https://www.statista.com/statistics/373408/orphan-drugs-by-phase-iii-development-cost/
Evaluate, Phase III R&D costs of projected top orphan drugs as of 2015 (in million U.S. dollars)* Statista, https://www.statista.com/statistics/373408/orphan-drugs-by-phase-iii-development-cost/ (last visited November 23, 2024)
Phase III R&D costs of projected top orphan drugs as of 2015 (in million U.S. dollars)* [Graph], Evaluate, October 30, 2015. [Online]. Available: https://www.statista.com/statistics/373408/orphan-drugs-by-phase-iii-development-cost/
